Autoimmune hemolytic anemia, adverse event to venetoclax

Farm Hosp. 2019 Sep 1;43(5):166-167. doi: 10.7399/fh.11230.
No abstract available

Publication types

  • Case Reports

MeSH terms

  • Adenine / analogs & derivatives
  • Aged
  • Anemia, Hemolytic, Autoimmune / chemically induced*
  • Anemia, Hemolytic, Autoimmune / drug therapy
  • Antineoplastic Agents / adverse effects*
  • Antineoplastic Agents / therapeutic use
  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Bridged Bicyclo Compounds, Heterocyclic / adverse effects*
  • Bridged Bicyclo Compounds, Heterocyclic / therapeutic use
  • Cyclophosphamide / administration & dosage
  • Doxorubicin / administration & dosage
  • Humans
  • Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy
  • Male
  • Methylprednisolone / therapeutic use
  • Piperidines
  • Prednisone / administration & dosage
  • Pyrazoles / administration & dosage
  • Pyrimidines / administration & dosage
  • Recurrence
  • Rituximab / administration & dosage
  • Salvage Therapy / adverse effects
  • Sulfonamides / adverse effects*
  • Sulfonamides / therapeutic use
  • Vincristine / administration & dosage

Substances

  • Antineoplastic Agents
  • Bridged Bicyclo Compounds, Heterocyclic
  • Piperidines
  • Pyrazoles
  • Pyrimidines
  • Sulfonamides
  • ibrutinib
  • Rituximab
  • Vincristine
  • Doxorubicin
  • Cyclophosphamide
  • Adenine
  • venetoclax
  • Prednisone
  • Methylprednisolone

Supplementary concepts

  • CHOP protocol